BofA lowered the firm’s price target on Teva (TEVA) to $20 from $23 and keeps a Buy rating on the shares. The firm revised lower its FY26 and FY27 EBITDA estimates by 4% and 1%, respectively, on read-through from competitor disclosure pertaining to generic Revlimid profitability, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Teva, Medincell announce FDA acceptance of sNDA for Uzedy
- FDA accepts Teva & Medincell’s UZEDY sNDA for extended-release to treat BP-I
- Teva Pharmaceutical’s Promising TL1a Program Drives Buy Rating Amid Strong Phase 2 Data for Duvakitug
- Teva holds a pharmaceutical update conference call
- Teva, Sanofi present new results from RELIEVE UCCD Phase 2b study